Observational Study

. 2021 Dec;2(12):1305-1320.

doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Annika Fendler^#¹, Scott T C Shepherd^#^{1

2}, Lewis Au^#^{1

2}, Katalin A Wilkinson^#^{3

4}, Mary Wu^#⁵, Fiona Byrne¹, Maddalena Cerrone^{3

6}, Andreas M Schmitt², Nalinie Joharatnam-Hogan², Benjamin Shum^{1

2}, Zayd Tippu², Karolina Rzeniewicz¹, Laura Amanda Boos², Ruth Harvey⁷, Eleanor Carlyle², Kim Edmonds², Lyra Del Rosario², Sarah Sarker², Karla Lingard², Mary Mangwende², Lucy Holt², Hamid Ahmod², Justine Korteweg², Tara Foley², Jessica Bazin⁸, William Gordon¹, Taja Barber¹, Andrea Emslie-Henry¹, Wenyi Xie¹, Camille L Gerard¹, Daqi Deng¹, Emma C Wall^{9

10}, Ana Agua-Doce¹¹, Sina Namjou¹², Simon Caidan¹², Mike Gavrielides¹³, James I MacRae¹⁴, Gavin Kelly¹⁵, Kema Peat², Denise Kelly², Aida Murra², Kayleigh Kelly², Molly O'Flaherty², Lauren Dowdie², Natalie Ash², Firza Gronthoud¹⁶, Robyn L Shea^{16

17}, Gail Gardner¹⁶, Darren Murray¹⁶, Fiona Kinnaird¹⁸, Wanyuan Cui¹⁹, Javier Pascual²⁰, Simon Rodney², Justin Mencel²¹, Olivia Curtis¹⁹, Clemency Stephenson⁸, Anna Robinson⁸, Bhavna Oza², Sheima Farag², Isla Leslie², Aljosja Rogiers², Sunil Iyengar⁸, Mark Ethell⁸, Christina Messiou²², David Cunningham²¹, Ian Chau²¹, Naureen Starling²¹, Nicholas Turner²⁰, Liam Welsh²³, Nicholas van As²⁴, Robin L Jones²⁵, Joanne Droney²⁶, Susana Banerjee²⁷, Kate C Tatham²⁸, Mary O'Brien¹⁹, Kevin Harrington^{29

30}, Shreerang Bhide^{29

30}, Alicia Okines^{20

31}, Alison Reid³², Kate Young², Andrew J S Furness², Lisa Pickering², Charles Swanton^{33

34}; Crick COVID-19 Consortium; Sonia Gandhi^{35

36}, Steve Gamblin¹⁰, David L V Bauer³⁷, George Kassiotis³⁸, Sacheen Kumar²¹, Nadia Yousaf^{19

31}, Shaman Jhanji²⁸, Emma Nicholson⁸, Michael Howell⁵, Susanna Walker²⁸, Robert J Wilkinson^{3

4

6}, James Larkin², Samra Turajlic^{39

40}; CAPTURE Consortium

Affiliations

¹ Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.
² Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.
³ Tuberculosis Laboratory, the Francis Crick Institute, London, UK.
⁴ Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory, Cape Town, Republic of South Africa.
⁵ High Throughput Screening Laboratory, the Francis Crick Institute, London, UK.
⁶ Department of Infectious Disease, Imperial College London, London, UK.
⁷ Worldwide Influenza Centre, the Francis Crick Institute, London, UK.
⁸ Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
⁹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, UK.
¹⁰ Structural Biology of Disease Processes Laboratory, the Francis Crick Institute, London, UK.
¹¹ Flow Cytometry Scientific Technology Platform, the Francis Crick Institute, London, UK.
¹² Safety, Health & Sustainability, the Francis Crick Institute, London, UK.
¹³ Scientific Computing Scientific Technology Platform, the Francis Crick Institute, London, UK.
¹⁴ Metabolomics Scientific Technology Platform, the Francis Crick Institute, London, UK.
¹⁵ Department of Bioinformatics and Biostatistics, the Francis Crick Institute, London, UK.
¹⁶ Department of Pathology, the Royal Marsden NHS Foundation Trust, London, UK.
¹⁷ Translational Cancer Biochemistry Laboratory, the Institute of Cancer Research, London, UK.
¹⁸ Clinical Trials Unit, the Royal Marsden NHS Foundation Trust, London, UK.
¹⁹ Lung Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁰ Breast Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²¹ Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²² Department of Radiology, the Royal Marsden NHS Foundation Trust, London, UK.
²³ Neuro-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁴ Clinical Oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁵ Sarcoma Unit, the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
²⁶ Palliative Medicine, the Royal Marsden NHS Foundation Trust, London, UK.
²⁷ Gynaecology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁸ Anaesthetics, Perioperative Medicine and Pain Department, the Royal Marsden NHS Foundation Trust, London, UK.
²⁹ Head and Neck Unit, the Royal Marsden NHS Foundation Trust, London, UK.
³⁰ Targeted Therapy Team, The Institute of Cancer Research, London, UK.
³¹ Acute Oncology Service, the Royal Marsden NHS Foundation Trust, London, UK.
³² Uro-oncology Unit, the Royal Marsden NHS Foundation Trust, Surrey, UK.
³³ Cancer Evolution and Genome Instability Laboratory, the Francis Crick Institute, London, UK.
³⁴ University College London Cancer Institute, London, UK.
³⁵ Neurodegeneration Biology Laboratory, the Francis Crick Institute, London, UK.
³⁶ UCL Queen Square Institute of Neurology, London, UK.
³⁷ RNA Virus Replication Laboratory, the Francis Crick Institute, London, UK.
³⁸ Retroviral Immunology Laboratory, the Francis Crick Institute, London, UK.
³⁹ Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.
⁴⁰ Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK. samra.turajlic@crick.ac.uk.

^# Contributed equally.

PMID: 35121899
DOI: 10.1038/s43018-021-00274-w

Observational Study

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Annika Fendler et al. Nat Cancer. 2021 Dec.

. 2021 Dec;2(12):1305-1320.

doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.

Authors

Affiliations

¹ Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK.
² Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK.
³ Tuberculosis Laboratory, the Francis Crick Institute, London, UK.
⁴ Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory, Cape Town, Republic of South Africa.
⁵ High Throughput Screening Laboratory, the Francis Crick Institute, London, UK.
⁶ Department of Infectious Disease, Imperial College London, London, UK.
⁷ Worldwide Influenza Centre, the Francis Crick Institute, London, UK.
⁸ Haemato-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
⁹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, UK.
¹⁰ Structural Biology of Disease Processes Laboratory, the Francis Crick Institute, London, UK.
¹¹ Flow Cytometry Scientific Technology Platform, the Francis Crick Institute, London, UK.
¹² Safety, Health & Sustainability, the Francis Crick Institute, London, UK.
¹³ Scientific Computing Scientific Technology Platform, the Francis Crick Institute, London, UK.
¹⁴ Metabolomics Scientific Technology Platform, the Francis Crick Institute, London, UK.
¹⁵ Department of Bioinformatics and Biostatistics, the Francis Crick Institute, London, UK.
¹⁶ Department of Pathology, the Royal Marsden NHS Foundation Trust, London, UK.
¹⁷ Translational Cancer Biochemistry Laboratory, the Institute of Cancer Research, London, UK.
¹⁸ Clinical Trials Unit, the Royal Marsden NHS Foundation Trust, London, UK.
¹⁹ Lung Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁰ Breast Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²¹ Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²² Department of Radiology, the Royal Marsden NHS Foundation Trust, London, UK.
²³ Neuro-oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁴ Clinical Oncology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁵ Sarcoma Unit, the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
²⁶ Palliative Medicine, the Royal Marsden NHS Foundation Trust, London, UK.
²⁷ Gynaecology Unit, the Royal Marsden NHS Foundation Trust, London, UK.
²⁸ Anaesthetics, Perioperative Medicine and Pain Department, the Royal Marsden NHS Foundation Trust, London, UK.
²⁹ Head and Neck Unit, the Royal Marsden NHS Foundation Trust, London, UK.
³⁰ Targeted Therapy Team, The Institute of Cancer Research, London, UK.
³¹ Acute Oncology Service, the Royal Marsden NHS Foundation Trust, London, UK.
³² Uro-oncology Unit, the Royal Marsden NHS Foundation Trust, Surrey, UK.
³³ Cancer Evolution and Genome Instability Laboratory, the Francis Crick Institute, London, UK.
³⁴ University College London Cancer Institute, London, UK.
³⁵ Neurodegeneration Biology Laboratory, the Francis Crick Institute, London, UK.
³⁶ UCL Queen Square Institute of Neurology, London, UK.
³⁷ RNA Virus Replication Laboratory, the Francis Crick Institute, London, UK.
³⁸ Retroviral Immunology Laboratory, the Francis Crick Institute, London, UK.
³⁹ Cancer Dynamics Laboratory, the Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.
⁴⁰ Skin and Renal Units, the Royal Marsden NHS Foundation Trust, London, UK. samra.turajlic@crick.ac.uk.

^# Contributed equally.

PMID: 35121899
DOI: 10.1038/s43018-021-00274-w

Abstract

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.

PubMed Disclaimer

Comment in

Capturing adaptive immunity against SARS-CoV-2 in patients with cancer.
Luxenburger H, Thimme R. Luxenburger H, et al. Nat Cancer. 2021 Dec;2(12):1298-1300. doi: 10.1038/s43018-021-00298-2. Nat Cancer. 2021. PMID: 35121915 No abstract available.

References

1. Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021). - DOI - PubMed - PMC
1. Public Health England. Confirmed Cases of COVID-19 Variants Identified in UK https://www.gov.uk/government/news/confirmed-cases-of-covid-19-variants-... (2021).
1. Public Health England and Department of Health and Social Care. COVID-19: Guidance on Protecting People Defined on Medical Grounds as Extremely Vulnerable https://www.gov.uk/government/publications/guidance-on-shielding-and-pro... (2021).
1. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461–2462 (2021). - DOI - PubMed - PMC
1. Brosh-Nissimov, T. et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect. https://doi.org/10.1016/j.cmi.2021.06.036 (2021).

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Supplementary concepts

Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Affiliations

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Authors

Affiliations

Abstract

Comment in

References

Publication types

MeSH terms

Substances

Supplementary concepts

Associated data

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous